We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward. This graphics represents key facts about the AIDS vaccine field.
HIV Vaccines by the Numbers: Trials, discoveries, money and more
AIDS Vaccine Science for Busy Advocates – Current AIDS Vaccine R&D Pipeline
One-pager reviewing what we’ve learned from previous efficacy trials, the product pipeline and where we are today and future directions toward finding a vaccine that works.
AIDS Vaccine Science for Busy Advocates – RV144: Building on a breakthrough
A one-page document describing RV144, the first AIDS vaccine trial to show protection against HIV in humans, and plans to further this research.
AIDS Vaccine Science for Busy Advocates – Passive Immunization: An important piece of the puzzle
A one-page document describing passive immunization, the transfer of pre-made antibodies, and its potential for HIV prevention.
HIV Vaccines: Key messages
This is a three-page document providing main points surrounding vaccine research. For a shorter one-page version of this, click here.
Pre-Exposure Prophylaxis: An introductory factsheet
This introductory 2-page document defines PrEP, reviews the scientific evidence to date, and outlines key research, regulatory and advocacy issues going forward. This factsheet is part of a series on emerging HIV prevention strategies.
Treatment as Prevention: An introductory factsheet
This introductory 2-page document defines treatment as prevention, reviews the scientific evidence behind it, and outlines implementation advocacy priorities. The factsheet is part of a series on emerging HIV prevention strategies.
Microbicides for HIV Prevention: An introductory factsheet
This introductory 2-page document defines microbicides and reviews the state of research on some leading candidates.
Multipurpose Prevention Technologies (MPTs): An introductory factsheet
This introductory 2-page document makes the case for why women need prevention options that protect them against multiple risks—HIV, STIs and/or pregnancy—and discusses the products that are being studied for this purpose. The factsheet is part of a series on emerging HIV prevention strategies.
Press Statement from Kenya AIDS Civil Society AIDS Groups Cheer First Major New Commitment by Presidential Candidate
This press release from a coalition of Kenyan civil society groups celebrates a success in an election-year campaign led by 2013 AVAC Advocacy Fellow Maureen Milanga to secure commitments to good HIV policy by political candidates. The pledge by Prime Minister Raila Odinga committed his administration, if elected, to provide universal access to antiretroviral therapy and to spend 15 percent of the national budget on healthcare.